NasdaqHealth CareHealth Care SuppliesS&P MidCap 400
$100.61
-0.09 (-0.09%)
Close of Nov 06, 2026 · end-of-day data
LNTH 8-K filings in 2026
Every material Form 8-K Lantheus filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lantheus reported third quarter 2026 revenue of $389.9 million, up 1.5%, while GAAP diluted earnings per share fell to $0.33 from $0.41 and adjusted diluted EPS rose to $1.68 from $1.27. The company suspended its full year 2026 guidance because of its pending all-cash merger with Curium, which values Lantheus at up to $8.0 billion including contingent value rights.
Worldwide revenue was $389.9 million, up 1.5% from $384.0 million a year earlier; GAAP net income fell 19.4% to $22.4 million.
Operating income decreased 26.2% to $32.2 million, including a $31.0 million impairment of intangible assets.
Full year 2026 financial guidance was suspended in connection with the pending merger with Curium.
Curium would pay $102.50 per share in cash plus up to $12.00 per share in contingent value rights, a total of up to $114.50 per share.
Lantheus and Curium's parent each received a Second Request from the FTC on October 21, 2026, in its review of the August 3, 2026 merger agreement. The request extends the HSR Act waiting period until 30 days after substantial compliance, so closing is pending longer, though the companies still expect completion in the first half of 2027.
FTC issued Second Requests to Lantheus and Parent on October 21, 2026
Waiting period extends until 30 days after both parties substantially comply with the requests
Companies still expect the merger to close in the first half of 2027
Lantheus reported second quarter 2026 revenue of $388.2 million, up 2.7% from a year earlier, while GAAP diluted earnings per share were $1.11 versus $1.12 and adjusted diluted earnings per share were $1.55 versus $1.57. The company suspended its full year 2026 guidance and will not hold a conference call, citing the pending merger with Curium announced August 3, 2026, under which shareholders would receive $102.50 per share in cash plus contingent value rights worth up to $12.00 per share.
Worldwide revenue of $388.2 million, up 2.7%; PYLARIFY sales of $240.4 million, down 4.1%
GAAP net income of $75.0 million, down 4.7%; adjusted net income of $104.9 million, down 5.1%
Full year 2026 guidance suspended in connection with the pending transaction
Merger consideration of $102.50 per share in cash plus CVRs of up to $12.00 per share; total transaction value of up to approximately $8.0 billion
Lantheus Holdings entered a merger agreement under which Curium US Holdings would acquire the company, with Lantheus surviving as a wholly owned subsidiary of Curium's parent. Shareholders would receive $102.50 per share in cash plus one contingent value right worth up to $12.00 per share upon certain commercial milestones, so the deal would end their ownership of the stock and its Nasdaq listing.
Cash consideration of $102.50 per share plus one CVR paying up to $12.00 in cash on specified commercial milestones
Closing requires stockholder approval, expiration or termination of the HSR waiting period, and other customary conditions; no financing condition
Either party may terminate if the merger is not completed by May 2, 2027, subject to extensions
Lantheus reported first quarter 2026 worldwide revenue of $377.3 million, up 1.2% from a year earlier, and GAAP diluted EPS of $1.80, up 76.5%. Adjusted diluted EPS fell 4.6% to $1.46, and PYLARIFY sales declined 6.5%, while the GAAP gain was boosted by a $59.3 million gain on the sale of the SPECT business. The company reaffirmed its full-year 2026 revenue guidance of $1.4 billion to $1.45 billion and adjusted diluted EPS guidance of $5.00 to $5.25.
Worldwide revenue rose 1.2% to $377.3 million; PYLARIFY sales were $240.9 million, down 6.5%
Adjusted diluted EPS was $1.46, down from $1.53; GAAP diluted EPS was $1.80, up from $1.02
Adjusted operating income decreased 10.5% to $129.1 million
Full-year 2026 guidance was reaffirmed: revenue of $1.4 billion to $1.45 billion and adjusted diluted EPS of $5.00 to $5.25
At its April 30, 2026 annual meeting, Lantheus shareholders approved a Delaware charter amendment to declassify the board over three years, after which directors may be removed with or without cause. They also approved the Amended and Restated 2026 Equity Incentive Plan, which adds 2,000,000 shares and caps non-employee director pay, and elected four Class II directors. For shareholders, the filing covers governance and compensation terms rather than financial results.
Certificate of Amendment filed April 30, 2026 with Delaware to declassify the board over a three-year period.
Equity plan adds 2,000,000 shares; non-employee director pay capped at $1,250,000 in the year of appointment and $750,000 in other years.
Shareholders chose one-year frequency for future advisory say-on-pay votes, so the board will hold them every year.
Deloitte & Touche LLP was ratified as independent auditor for the fiscal year ending December 31, 2026.
Lantheus reported fourth-quarter 2025 revenue of $406.8 million, up 4.0%, and GAAP diluted EPS of $0.82 versus a loss of $(0.17) a year earlier. For full year 2025, revenue was $1.54 billion, up 0.5%, while adjusted diluted EPS fell to $6.08 from $6.76. The company also said it is pursuing value-maximizing alternatives for its radiotherapeutic assets and issued 2026 revenue guidance of $1.4 billion to $1.45 billion and adjusted diluted EPS guidance of $5.00 to $5.25.
Q4 2025 revenue $406.8 million, up 4.0%; Q4 adjusted operating income down 8.5% to $138.9 million
Full year 2025 GAAP diluted EPS $3.41 versus $4.36 in 2024; adjusted diluted EPS $6.08 versus $6.76
Company repurchased $100 million of common stock in Q4 2025 and completed the divestiture of the legacy SPECT business to SHINE Technologies effective January 1, 2026
FY 2026 guidance: revenue $1.4 billion to $1.45 billion; adjusted diluted EPS $5.00 to $5.25
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lantheus filing is on SEC EDGAR ↗. 8-K briefs of other companies →